This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Journal of Hematology & Oncology Open Access 06 January 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original articles
Burchert, A. et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3–internal tandem duplication mutation (SORMAIN). J. Clin. Oncol. https://doi.org/10.1200/JCO.19.03345 (2020)
Xuan, L. et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30455-1 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Sorafenib prevents AML relapse after allo-HSCT. Nat Rev Clin Oncol 17, 591 (2020). https://doi.org/10.1038/s41571-020-00431-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-020-00431-7
This article is cited by
-
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Journal of Hematology & Oncology (2021)